Hikal Limited (HIKAL) has marked a significant milestone with the successful commercial production of its Personal Care products from its new cGMP-compliant, multipurpose manufacturing facility in Panoli, Gujarat. This new facility represents Hikal’s formal entry into the commercial-scale supply for the global beauty and personal care industry, aligning with the company’s broader strategy of building new, high-value growth platforms alongside its established Pharmaceuticals, Crop Protection, and Animal Healthcare businesses.

Strategic Entry into Personal Care

As part of its strategic commitment to this new segment, Hikal repurposed an existing manufacturing asset at Panoli to serve the evolving needs of the global beauty and personal care industry. The facility has recently commenced commercial production and successfully manufactured its first production batches. Product samples have been validated with customers, and the company has received encouraging feedback, resulting in a positive market pull for its product portfolio.

Focus on Beauty & Personal Care

Hikal’s initial focus within Personal Care is on the Beauty & Personal Care segment, particularly the skin care category, where demand continues to grow globally. The company has built a strong portfolio of second-generation UV filters, offering enhanced performance and closer alignment with evolving consumer preferences and tightening regulatory requirements across key markets. These products are undergoing approvals by its global customers, as part of Hikal’s continued strategy of portfolio diversification beyond its core Pharma and Crop Protection segments.

“Personal Care represents the kind of long-term opportunity we look for. We’ve applied the same disciplined approach that built our Pharmaceuticals and Crop Protection businesses, deep customer partnerships, rigorous quality systems, and patient capital investment, to a new category where global demand for specialty skincare ingredients is accelerating. Commissioning the Panoli facility, manufacturing our first production batches, and securing positive customer feedback points towards the growth of the business in the coming years,” said Sameer Hiremath, Vice Chairman & Managing Director, Hikal Limited.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 61% of its 52-week range with RSI at 53. In other words, neither side has a clear edge right now. Price climbs recently despite -5.4% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Hikal Limited.

Park Medi World Limited (NSE: PARKHOSPS) has been recognised with three honours at the prestigious Healthcare Pioneers of Delhi 2026 awards. The accolades were presented by Smt. Rekha Gupta, Hon’ble Chief Minister of Delhi, at The Imperial Hotel, Janpath, New Delhi on 20th September 2026. The recognition highlights the Group’s commitment to clinical outcomes, advanced medical technology, and expanding presence across North India.

Lifetime Achievement Award

Dr. Ajit Gupta, Founder & Chairman, received the Lifetime Achievement Award. This honour reflects his long-standing dedication to healthcare excellence.

Future Healthcare Leader of the Year

Dr. Ankit Gupta, Managing Director, was named Future Healthcare Leader of the Year. This recognition underscores his leadership in scaling capacity and investing in advanced medical technology.

Excellence in Advanced Medical Technology & Patient Care

Park Group of Hospitals was awarded Excellence in Advanced Medical Technology & Patient Care. This accolade highlights the Group’s commitment to providing high-quality, affordable healthcare services.

As Park Medi World Limited continues to expand its network, it aims to build a dependable, technology-enabled healthcare ecosystem that serves both metropolitan and regional communities across North India. For more information, visit www.parkhospital.in.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Park Medi World Limited

Park Medi World Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Park holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 7.91 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -0.7% in three months on 9.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Park Medi World Limited.

Biocon Limited (NSE: BIOCON) announced that its Pertuzumab biosimilar has become the first biosimilar to secure a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval recommendation under the new tailored clinical approach marks a significant milestone for Biocon Biologics Limited, a wholly-owned subsidiary of Biocon Limited. The biosimilar, marketed under the brand name Pebrilzo®, is indicated for the treatment of HER2-positive breast cancer across multiple disease stages.

Extensive Clinical and Analytical Validation

The positive CHMP opinion follows a comprehensive review of the marketing authorization application submitted by Biocon Biologics Ireland Limited. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Pebrilzo® is highly similar to the reference biologic, with no clinically meaningful differences in quality, safety, or efficacy.

Expanding Access to Biologic Therapies

Shreehas Tambe, CEO & Managing Director of Biocon, said: “The positive CHMP opinion for our Pertuzumab biosimilar marks an important step toward expanding access to biologic therapies for patients with HER2-positive breast cancer in Europe.” This approval reflects an important milestone in the evolution of biosimilar science and greater regulatory confidence on advanced analytical and clinical pharmacology evidence to establish biosimilarity.

As the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA’s tailored clinical development approach, this approval is a testament to Biocon’s commitment to providing affordable, life-changing medicines to patients worldwide.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 44% of its 52-week range with RSI at 35. In other words, neither side has a clear edge right now. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.